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Abstract 
Background 
The World Health Organization (WHO) recommends praziquantel for the control and treatment of 
schistosomiasis, with no real alternative. Pre-school children are excluded from population 
treatment programs mainly due to paucity of safety data on this age group.  
Objectives: This study investigated safety, efficacy and acceptability of praziquantel for the 
treatment of S. haematobium and S. mansoni infections among pre-school children aged <6years. 
The study also investigated the burden of schistosomiasis in this age group. 
Methods: Pre-school children (n=188) from Sudan were included in the study. The children were 
treated with praziquantel tablets at a single dose of 40 mg/kg body weight. Adverse events were 
assessed at 24 hours and 7 days later, via questionnaire administration to parents and guardians. 
Efficacy of treatment was assessed at 1, 3 and 6 months by examining stool and urine samples for 
schistosome eggs. Acceptability was determined by the number of children spitting or vomiting 
during administration of the drug.  
Results: The burden of schistosomiasis among pre-school children aged <6 years was high 
(31.1%), and this was comparable to that observed among school children-aged ≥6 years (32%). 
Praziquantel treatment achieved high cure rates (egg negative) for both S. haematobium and S.
mansoni infections when assessed at 1 month after treatment (89.6-92.1%) and remained high for S.
haematobium (89.6-100%) up to 6 months. However, cure rate dropped from 90.5% at one month 
to 58.8% and 69.2% at 3 and 6 months among S. mansoni-treated children. Praziquantel treatment 
decreased egg counts considerably with post-treatment geometric mean egg reductions rates ranging 
from 96.4% to 99.4% at 1 month. Acceptability of praziquantel treatment was high, only for one 
child the dose had to be repeated after initial spitting. Treatment resolved haematuria and improved 
weight of the children. There were no drug-related adverse events in all the treated children during 
follow-up at 24 hours and 7 days. 
Conclusions: Praziquantel is safe, effective and acceptable among children aged <6 years. Pre-
school children represent a high risk group for schistosomiasis and should be included in population 
treatment programs. 
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account for about 85% of the global burden of 
the disease1, 2, 3. In most African countries, 
there is an overlap of the two schistosome 
species resulting in mixed infections4.
Continuous exposure to contaminated water 
causes repeated infections during childhood 
but severe-chronic disease appears later in 
life. Other, more subtle, effects of the 
infection in school children include short-
term memory loss, slower reaction time, 
lower scores in some tests of cognitive ability, 
and poor growth5,4. Anaemia and other 
nutritional deficiencies have also been linked 
with the infection6.
The disease can be prevented or the 
underlying pathology reversed by treatment 
with praziquantel, the anti-schistosomal drug 
of choice7,-13 . With the high price of 
praziquantel following its discovery in the 
late 1970s, experts suggested that selective 
treatment i.e. identification of high prevalence 
communities, screening the people and 
treating those identified to have the infection 
would be more cost-effective14. Also, 
intensity of infection is highest in children 
and adolescents, hence treatment should be 
targeted to school-aged     children15,4,10.
Within this approach the standard single dose 
of 40 mg/kg of praziquantel is recommended 
14, 4. In parts of sub-Saharan Africa, 
population-based treatment campaign 
programs remain the only option for most 
individuals suffering from schistosomiasis to 
receive treatment9.
Since the early millennium, however, 
praziquantel use has increased considerably 
mainly due to the sharp fall in price16, 17. The 
finding of a meta-analysis that first suggested 
that although emergence of clinical resistance 
could not be ruled completely out, there was 
no eminent threat to praziquantel, contributed 
to the adoption of the policy for mass 
distribution of this drug to endemic 
countries18. A recent study also concluded 
that there is no evidence to suggest that 
resistance against praziquantel has emerged, 
or is emerging17. The 54th World Health 
Assembly endorsed mass drug distribution 
and treatment of at least 75% of school-aged 
children and other high-risk groups with 
praziquantel by 20104. The Schistosomiasis 
Control Initiative (SCI), started in 2003 and 
supported by Bill and Melinda Gates, has 
been in the forefront of these large-scale 
control programs across selected countries in 
sub-Saharan Africa16, 19.However,   
pre-school children under 5 five years have 
been excluded from population  treatment  
programmes20 There is emerging evidence 
that the burden of schistosomiasis is high in 
pre-school children and the World Health 
Organization (WHO) is considering a 
recommendation that will include pre-school 
children and infants in population treatment 
programs. However, there is paucity of safety 
and efficacy data on praziquantel in pre-
school children aged <5 years21. In order to 
contribute evidence to inform treatment 
policies, this study was sponsored by WHO to 
assess safety, efficacy and acceptability of 
praziquantel among pre-school children in 
schistosomiasis endemic area along the 
Gezira Irrigation Scheme in Sudan. The study 
was also to document the extent of 
schistosomiasis burden in pre-school children 
by determining prevalence and intensity of S.
haematobium and S. mansoni; to describe 
morbidity related to schistosomiasis from 
micro and macro haematuria. With most 
population treatment administered without 
prior diagnosis in the approach termed 
'preventive chemotherapy' - the control 
strategy currently recommended by the WHO 
and applied in many endemic countries4,22,
this study also assessed age-specific 
prevalence rates within this age group to 
inform on the age at which treatment should 
best be initiated.  
 
Materials and Methods 
Ethical clearance 
 Ethical clearance for the study was obtained 
from WHO’s Research Ethics Review 
Committee,  
National Ministry of Health and Ahfad 
University for Women in Sudan. Parents and 
guardians were adequately informed about the 
treatment and possible treatment-related side-
effects and what they should do in the event 
of side effects. Written consent of a child to 
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participate in the study was obtained from 
household heads, parents or guardians. 
Study area and population  
This study was conducted in Hassahesa and 
Kamlin localities in the Gezira Irrigation 
Scheme, Gezira State, Sudan. The Irrigation 
Scheme was initiated in 1924 and located 
between the Blue and White Niles, South 
Khartoum. The scheme provides over 
800,000 hectares of farm land intended to 
boost agricultural production, but this in turn 
has favoured breeding of the intermediate 
host snails responsible for transmission of 
schistosomiasis. The inhabitants in this area 
are mainly Arab tenants who live with their 
families, but there are also non-tenant Arabs. 
Outside of Arab villages there is scattered 
population of workers from west Sudan and 
migrants from neighboring countries who live 
either in camps or in unregistered villages 
without health services, electricity clean piped 
water supply or schools. The children can 
attend the nearest primary school and some 
immigrants make use of the nearby 
dispensary or dressing station. In 1985 the 
total permanent and migrant population was 
estimated to be 2 million23.The estimate of the 
population of the Gezira State in 2009 was 
over 3.6 million24. A detailed description of 
the Gezira Irrigation Scheme has been 
reported elsewhere25.
School surveys 
Surveys were conducted in primary schools to 
identify villages with schistosomiasis 
prevalence rates greater than 40%. On the 
basis of the prevalence in the school surveys, 
10 villages were further surveyed for 
schistosomiasis in pre-school children aged 
<6 years.  Three villages namely, Hilat 
Daoud, Branco and Hamad Alla were then 
selected.  S. haematobium is the predominant 
species in Hilat Daoud and Branco whilst 
Hamad Alla is mainly endemic for S.
mansoni.
Parasitological diagnosis of the infection 
The Kato-Katz method 26 was used for 
parasitological diagnosis of the infection and 
egg count was expressed as eggs per gram 
(epg) of stool. Three slides were examined 
from a single stool sample. S. haematobium 
was diagnosed by the urine filtration 
technique and egg count expressed as eggs 
per 10 ml of urine27.The intensity of infection 
was categorized according to the WHO 
classification as light infection (1 to 99 epg) 
moderate (100 to 399 epg) and heavy (�400
epg) for S. mansoni and for S. haematobium,
light infection was (≤50 eggs/10ml urine) and 
heavy was (�50 eggs/10 ml).  
Clinical examination 
All the children underwent clinical 
examination before treatment was given. 
Urine samples of participating children were 
examined and 103 (74.6%) had abnormal 
urine color, mainly blood in urine 
(haematuria).  Abdominal pain was also 
prevalent among these children and infants 
(n=78; 56.5%). Only three children (2.2%) 
reported general fatigue. General physical 
examinations and anthropometric 
measurements revealed that 11 patients (8%) 
had stunted growth (Height-for-age <3rd 
percentile); 9 patients (6.5%) were under 
weight according to Welcome classification 
of malnutrition. Hepatosplenomegaly was not 
common among these children but in case it 
was detected the affected child was referred 
to the district hospital for further evaluation 
and management. Children with umbilical 
hernias were also referred. The children with 
vitamin A deficiency were given therapeutic 
doses of vitamin A. Children with other minor 
infections were treated with the appropriate 
medication.  
Treatment 
Praziquantel tablets (Distocide, Batch No. 
DISTT 4010) made in Korea, and provided by 
the WHO was used for treating the pre-school 
children in this study. Each child was 
weighed using a calibrated weighing scale 
and a single dose of 40 mg/kg praziquantel 
was administered. For children aged 1-3 
years, their weight ranged from 6-20 kg 
(mean, 13 kg), and the corresponding mean 
dose administered was 518 mg with the 
number of tablets a child received ranging 
from � -1� (mean, 1 tablet). Children aged 3-
5 years had weight ranging from 12-28 kg 
(mean, 18.6 kg) and the mean dose was 740 
mg, with the number of tablets ranging from 
Mutamad A. Amin et al.                                  Treatment of pre-school children for schistosomiasis 
 
© Sudan JMS Vol. 7, No.2. June 2012 70
1-2 (mean 1¼ tablet). The 5-6 year old 
children had weight ranging from 17.5-33 kg 
(mean, 24.5kg), mean dose (977 mg) and the 
corresponding number of tablets ranging from 
¼-2¼ (mean, 1� tablet). The praziquantel 
tablets were broken into pieces before 
administration. For children who could not 
swallow, the tablets were crushed and 
administered with honey to decrease the bitter 
taste. The drug administration was supervised 
using a modified Direct Observation Therapy 
(DOT). All the children included in the study 
received a snack before the drug was 
administered. The mothers or guardians of the 
treated children were interviewed 24 hours 
and 7 days post treatment by the clinician 
using structured questionnaire for episodes of 
treatment-related side effects. The children 
were followed (less actively) until 6 months 
to record adverse events. At each of the visits, 
specific signs and symptoms (abdominal pain, 
nausea, vomiting, diarrhoea, anorexia, fever, 
headache, dizziness and fever) were 
evaluated. Other symptoms reported by 
parents or guardians were also recorded. Each 
symptom was classified according to severity 
as mild, moderate, severe or life-threatening; 
seriousness was assessed using a grading 
scale. The symptoms were graded as not 
related, unlikely, possible, probable, most 
probable or insufficient data to enable 
adequate assessment. The efficacy of 
praziquantel was assessed at one, three and 
six months using the same diagnostic criteria 
as baseline. Any treated child presenting stool 
sample from which three slides were free for 
schistosome eggs or no eggs found in 10 ml 
of urine was considered to be cured. In this 
study treatment acceptability was defined as 
the number of children spitting or vomiting 
during administration of the drug, and it was 
assessed by direct observation therapy (DOT). 
The weight of children was measured using a 
calibrated weighing scale; heights were 
measured using a stadiometer with a flat 
wooden base. 
Inclusion and exclusion criteria 
Pre-school children under six years of age 
with confirmed schistosomiasis by 
microscopy were eligible for inclusion in the 
study. Seriously ill children; or children 
reporting a history of epilepsy, other signs of 
potential central nervous system involvement 
such as subcutaneous nodules suggestive of 
cystercosis; or have previously suffered one 
of the rare serious adverse events such as 
Stevens-Johnson syndrome, were excluded. 
These criteria were based on the World 
Health Organization (WHO) Manual of 
Preventive Chemotherapy22. Over all, one 
hundred and eighty-eight pre-school children 
were included in the study.  
 
Results 
Overall, prevalence of schistosomiasis among 
pre-school children in the three selected study 
villages (n=604) was high (31.1%). Urine 
examination revealed that in Branco a high 
number of pre-school children were infected 
with S. haematobium (43%); this was 22% in 
Hilat Daoud. The prevalence of S. mansoni in 
Hamad Alla was also high (44%). Age-
specific prevalence rates in the three villages 
have been reported in (Table 1). There was no 
significant difference across age-specific 
categories in this group in Hilat Daoud and 
Branco, but differences were observed in 
Hamad Alla (p�0.005). Strikingly, the rates of 
infection with schistosomiasis in pre-school 
children aged <6 years was comparable to 
that observed among school children aged ≥6
years in the 26 primary schools surveyed 
(n=1,427): 31.1% versus 32%, respectively.  
In this study praziquantel treatment achieved 
high cure rates (egg negative rates) for both S.
haematobium and S. mansoni infections at 1 
month and remained high for S. haematobium 
at 3 and 6 months (Table 2). Fifty-nine of 77 
(76.6%) children assessed at baseline who 
were found with S. haematobium were 
available for treatment in Hilat Daoud with a 
respondent rate of 76.6%. Of these 48 (81%) 
children were available at one month’s 
follow-up, 36 (61%) at three months and 29 
(49%) at six months. The overall cure rate 
was 89.6%, 91.6% and 100% at one month, 
and three and six months, respectively. In 
Branco, 50 of 64 (70.1%) children were 
available for treatment and 38 (76%) children 
were available at one month’s follow- up, 35 
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(70%) at three months and 36 (72%) at six 
months follow-up. The cure rates were 
92.1%% at one month, 91.4% at three months 
and 91.7% at six months. In Hamad Alla 29 
of 47 (61.8%) children found to have S. 
mansoni infection were available for 
treatment. Of these 21 (72%) children 
attended for follow-up assessment at one 
month, 17 (59%) children at three months and 
13 (45%) children at six months. The cure 
rate was 90.5% at one month, but this 
dropped to 58.8% at 1 month and 69.2% at 6 
months. Instability and lack of cooperation of 
the inhabitants contributed to the low turn out 
rate at follow-up in this village. 
For the two villages investigated for S. 
haematobium infections, the geometric mean 
egg count was higher for children in Hilat 
Dauod (166.1 eggs/10ml) than in Branco 
(28.2 eggs/10ml). Egg reduction rates were 
very high one month after treatment: in the 
children from Hilat Dauod egg count reduced 
to 1.5 eggs/10ml (a reduction of 99.4%) and 
in Branco to 1.3 eggs/10ml (a reduction of 
96.4%). The pretreatment geometric mean 
egg count for S. mansoni infection in the 
children from Hamad Alla was 97.8 epg and 
reduced to 1.5 epg after one month after 
treatment leading to a reduction rate of 99.0% 
(Figure1).   
All children accepted the drug without 
spitting or vomiting except for one child aged 
1½ years for whom the dose was repeated. 
However, dose determination, preparation and 
administration of the medication in this study 
were cumbersome.  During post-treatment 
follow-up visits and contacts after 24 hours 
and 7 days, when the children and their 
parents or guardians were asked about drug 
related side effects including gastro intestinal 
symptoms, skin manifestations, bleeding 
episodes, dizziness, general fatigue or change 
in gait or behaviour, no side effects were 
reported in all the treated children. Also, 
during the less active follow-up at 3 and 6 
months, no events were recorded. 
For anthropometry measurements, a 
significant increase in weight in children from 
Hilat Daoud (P�0.005) was observed one 
month after treatment (Figure 2). 
 









1-3 >3-5 >5-6 
No. Examined  94 176 80 350 
No. positive  21 32 24 77 
Prevalence  22.3% 18.2% 30% 22% 
Branco S. haematobium  
No. Examined   43 82 23 148 
No. positive   14 36 14 64 
Prevalence  32.6% 43.9% 60.9% 43.2% 
Hamad Alla S. mansoni  
No. Examined  33 54 19 106 
No. positive  6 29 12 47 
Prevalence  18.2% 53.7% 63.2% 44.3% 
Total positive  41 97 50 188 
Prevalence 24.1% 31% 41% 31.1% 
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Table2. Results of follow-up urine and stool examinations. 
 
Village 
 Follow-up examinations 
No. 
treated 




















Daoud 59 48 43 89.6  36 33 91.6 29 29 100 
Branco 50 38 35 92.1 35  32  91.4  36 33 91.7 
Hamad 
Alla 29 21 19 90.5 17 10 58.8 13 9 69.2 
Discussion 
This study revealed that the prevalence of 
schistosomiasis in pre-school children from 
the three selected villages was high (31.1%), 
comparable to that observed among school 
children aged ≥6 years (32%) in the 26 
primary schools surveyed (n=1,427). The 
findings are consistent with emerging 
evidence that the burden of schistosomiasis is 
high in pre-school children 21. In Ghana, a 
study investigating the extent of 
schistosomiasis in pre-school children and 
infants found prevalence of 11.2% for S.
haematobium, with the highest egg count 
detected in a 4-month old infant 28. In a rural 
endemic area in Nigeria, prevalence of 58.1% 
was reported for S. haematobium in children 
aged 1-6 years 29, whereas in Niger, rates of 
the infection among infants and their mothers 
were 61% and 72%, respectively 30. Similar 
findings have emerged from Mali where 
prevalence of S. haematobium among pre-
school children aged 1-4 years was found to 
be 51.2% 31. In Uganda nearly 50% of 
children less than three years of age living 
along the northern shoreline of Lake Victoria 
had S. mansoni infections 32. A recent study 
from the shoreline villages of Lakes Albert 
and Victoria in Uganda found even higher 
prevalence of S. mansoni (62.3%) in pre-
school children 33. In Sudan, an earlier study 
found high prevalence of schistosome 
infection (40%) among pre-school children in 
the Gezira Irrigation Scheme 34. The common 
feature associated with infection in these 
children from the various settings is that the 
children and their caregivers (parents or  
 
guardians) have high levels of water contact 
and thus intense exposure to the infective 
parasite.  
The implications of these findings are serious 
in the sense that since the advent of safe and 
efficacious drugs that shifted the focus of 
schistosomiasis control to individual or 
population-based chemotherapy, pre-school 
children have been excluded from such 
interventions mainly due to paucity of data to 
document the safety of praziquantel in this 
age group4. Other reasons for excluding pre-
school children from population 
chemotherapy programs include the 
following: these children cannot swallow 
praziquantel tablets and when the tablets are 
broken or crushed they reject it mainly 
because of the bitter taste; syrup formulations 
are not readily available; and the WHO 
recommended dose-pole for determining dose 
of praziquantel applied in control programs 
only works for children of height >94cm20.
Therefore, the suggestion was that pre-school 
children and infants should seek treatment in 
the regular health service or clinics. These 
facilities on the other hand deal with 
symptomatic cases and only the children 
presenting with symptoms would obtain 
treatment, which also is dependent on 
whether their parents or guardians would send 
them to health facilities at all. It means that 
even if a child has heavy worm burden but 
does not show symptoms, he/she is unlikely 
to receive treatment. However, without early 
treatment, schistosomiasis in children often 
leads to serious health consequences 
including nutritional deficiencies,
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Fig.1. Geometric means of egg counts in 
Hilat Daoud, Branco and Hamad Alla before 
and one month after treatment 
 
Fig.2.Means of weight in Hilat Daoud before 
and one month after treatment. 
 
retarded growth, reduced physical activity, 
and impaired cognitive function35,4. Another 
concern is that schistosomiasis is associated 
with rural dwelling36,37 and in such settings 
the peripheral health facilities where parents 
would send their children for treatment for 
schistosomiasis are mostly not available or 
nonfunctional. Even if available, these 
peripheral health facilities are faced with 
difficulties from lack diagnostic capacity and 
availability of praziquantel making it less 
likely for infected children to obtain the much 
needed intervention38,39. Also, whereas 
population-based schistosomiasis 
chemotherapy interventions delivered through 
vertical programs are free of charge40, visiting 
regular health care facilities is not free and the 
money charged may deter parents and 
guardians from seeking treatment from these 
facilities. Perceived seriousness of 
schistosomiasis-related symptoms which is 
usually underestimated at the community 
level may decrease the tendency for obtaining 
treatment for these vulnerable children41.
Therefore, for some who are unable to seek 
health care from the regular health facilities, 
their disease-related morbidity has not been 
averted raising serious public health concern 
for leaving pre-school children out of 
population-based chemotherapy campaign 
programmes42. Results of recent Cochrane 
systematic review showed that treatment with 
the standard dose of praziquantel (40 mg/kg) 
generally results in cure rates of ≥80% 1-3 
months after treatment43. In this study 
praziquantel achieved high cure rates of 89.6–
91.4% against S. haematobium and 90.5% 
against S. mansoni infections 1 month after 
treatment. Strikingly, cure rate from S.
haematobium treatment rose to 100% at 6 
months but that of S. mansoni dropped to 
58.8% at 3 months and 69.2% at 6 months. 
This observation, particularly the former, 
calls for caution when interpreting these 
findings as high losses to follow-up were 
experienced in the study mainly as a 
consequent of civil disturbances in the study 
setting at the time of the trial. The drop in 
cure rate over time for S. mansoni infection 
may be explained by factors such as rapid re-
infection rate after treatment, high 
pretreatment worm load that could not be 
completely cleared by the treatment that 
remained in the treated children and started 
producing eggs, and the presence of high 
numbers of immature worms less sensitive to 
praziquantel that escaped drug action and 
matured to egg producing worms during 
subsequent follow-ups18; praziquantel is 
refractory against immature worms43. The 
effect of treatment in terms of egg reduction 
rates ranging from 96.4–99.4% was high and 
supported by evidence of Cochrane 
systematic review44.
No drug-related adverse events were recorded 
or reported for the treatment of pre-school 
children with praziquantel during follow-up 
visits at 24 hours and 7 days. Possible bias 
could not be ruled as parents or guardians 
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reported side-effects on behalf of their 
preschool children who could not speak for 
themselves. However, in other studies 
involving pre-school children, minor and 
transient side-effects 24 hours after treatment 
were reported in Uganda 33, in Zimbabwe 45 
and in Mali 31 in accordance with established 
evidence that praziquantel is associated with 
minor and transient adverse events46,47.
Conclusions and recommendations  
The results of this study shows that 
chemotherapy with praziquantel against S.
haematobium and S. mansoni in pre-school 
children aged <6 years is safe, effective and 
acceptable. Therefore, these young children 
should be included in the national treatment 
control programs in order to prevent long-
term chronic ill-health or schistosomiasis-
related complications later in life. Given the 
cumbersome nature of dose determination, 
preparation and administration, it is important 
for manufacturers to come with smaller or 
easy to break tablets.  
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